Bacterial Vaginosis Therapeutic Pipeline
Dallas, TX (PRWEB) January 02, 2015
The report "Bacterial Vaginosis Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Bacterial Vaginosis. Bacterial vaginosis is a syndrome of the vagina caused by bacteria. Bacterial vaginosis is not a sexually transmitted infection but the risk factor for Bacterial vaginosis includes douching and having new or several sex partners. The most common symptom of Bacterial vaginosis is an abnormal homogeneous off-white vaginal discharge that may be accompanied by an unpleasant smell. Bacterial vaginosis can usually be effectively treated using a short course of antibiotic drug or an antibiotic gel. Complete Report is Available @ http://www.reportsnreports.com/reports/321897-bacterial-vaginosis-pipeline-review-h2-2014.html .
It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects. Companies discussed in this Bacterial Vaginosis Pipeline Review H2 2014 report include AmVac AG, Osel Inc., Starpharma Holdings Limited, Valeant Pharmaceuticals International, Inc.
Drugs profile discussed in this Bacterial Vaginosis Pipeline Review H2 2014 report include AMV-100, astodrimer, benzoyl peroxide, LACTIN-V, Peptide for Bacterial Vaginosis, Product-55394, secnidazole. Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=321897 .
Featured News & Press Releases
- Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis
- Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
- Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis
- Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis
- Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis
- Jun 25, 2012: Starpharma Completes Patient Recruitment For Phase II And First Pivotal Phase III Trials Of VivaGel
- Jun 04, 2012: Starpharma Completes 60% Patient Recruitment For Phase III Trials Of VivaGel
- Jan 11, 2012: Starpharma Receives FDA Special Protocol Assessment For Phase III Trials Of VivaGel For Treatment Of Bacterial Vaginosis
- Nov 21, 2011: Starpharma Secures European Agreement On BV Phase III Treatment
- Oct 10, 2011: Starpharma Secures FDA Agreement On Phase III VivaGel Bacterial Vaginosis Treatment Program
List of Tables
Number of Products under Development for Bacterial Vaginosis, H2 2014 7
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Bacterial Vaginosis - Pipeline by AmVac AG, H2 2014 16
Bacterial Vaginosis - Pipeline by Osel Inc., H2 2014 17
Bacterial Vaginosis - Pipeline by Starpharma Holdings Limited, H2 2014 18
Bacterial Vaginosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Bacterial Vaginosis Therapeutics - Recent Pipeline Updates, H2 2014 33
Bacterial Vaginosis - Dormant Projects, H2 2014 37
Bacterial Vaginosis - Discontinued Products, H2 2014 38
List of Figures
Number of Products under Development for Bacterial Vaginosis, H2 2014 7
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Routes of Administration, H2 2014 21
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 22
Number of Products by Top 10 Molecule Types, H2 2014 23
Number of Products by Stage and Top 10 Molecule Types, H2 2014 24
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.